|
PUBLICATIONS
PURI, RAJIV; PALIT, VICTOR;
LOADMAN, PAUL M.; FLANNIGAN, MICHAEL; SHAH, TARIQ; CHOUDRY,
GUZANFAR A.; BASU, SAURAJYOTI; DOUBLE, JOHN A.; LENAZ, GINO;
CHAWLA, SHANTA; BEER, MARIO; VAN KALKEN, COEN; DE BOER, RICHARD;
BEIJNEN, JOS H.; TWELVES, CHRISTOPHER J.; PHILLIPS, ROGER
M.
Phase I/II
Pilot Study of Intravesical Apaziquone (EO9) for Superficial
Bladder Cancer. Journal of Urology. 176(4):1344-1348, October
2006.
VAN DER HEIJDEN, ANTOINE G.;
MOONEN, PAULA M.J.; CORNEL, ERIK B.; VERGUNST, HENK; DE REIJKE,
THEO M.; VAN BOVEN, ERIKA; BARTEN, EVERT J.; PURI, RAJIV;
VAN KALKEN, COENRAAD K.; WITJES, J. ALFRED *
Phase II Marker
Lesion Study With Intravesical Instillation of Apaziquone
for Superficial Bladder Cancer: Toxicity and Marker Response.
Journal of Urology. 176(4):1349-1353, October 2006.
CLARKE, NICHOLAS S.; BASU, SAURAJYOTI;
PRESCOTT, STEVEN *; PURI, RAJIV
Chemo-prevention in superficial
bladder cancer using mitomycin C: a survey of the practice
patterns of British urologists. BJU International. 97(4):716-719,
April 2006.
JAIN, A.; TYSON, D.; PURI,
R.
How continence
returns after radical retropubic prostatectomy: a prospective
questionnaire based analysis: P109. BJU International. 97
Supplement 3:81, June 2006.
CHERIAN, J.; VODOVNIK, A.; SHAH,
T.; PURI, R.; LOADMAN, P.; PHILLIPS, R.
Expression of matrix metalloproteinases
and tissue inhibitors of metalloproteinases in carcinoma in
situ of bladder correlates with response to intravesical therapy
and disease progression: P006. BJU International. 97 Supplement
3:29, June 2006.
Palit, V.; Shah, T.; Biyani,
C. S.; Elmasry, Y.; Sarkar, R.; Flannigan, G. M.;
Puri, R.
Long Term
Follow Up of Men with Alfuzosin who Voided Successfully Following
Acute Urinary Retention[white star]. International Urology
& Nephrology. 37(3):507-510, September 2005.
CONNOLLY, J.; FLANNIGAN, G. M.;
CATCHPOLE, A.; SHAH, T. K.; PURI, R.; MASON, C.
Meeting bladder cancer waiting
time targets using improved communications across the haematuria
pathway - the benefits of an integrated care electronic patient
record and novel ways to inform patients: P46. BJU International
- Supplement. 95 Supplement 5:51, June 2005.
BASU, S. $; MUSTAFA, A. $; GUPTA,
S. K. #; URWIN, G. *; PURI, R. $
Audit of an
audit: validation of the Yorkshire regional radical prostatectomy
database. Prostate Cancer & Prostatic Diseases. 7(4):387-388,
December 2004.
PALIT, V.; PHILLIPS, R. M.; BIBBY,
M. C.; BATEMAN, P.; SHAH, T.; PURI, R.; FLANNIGAN,
G. M.
Expression
and clinical significance of Glucose transporter protein (GLUT-1)
during progression of human prostate cancer. Prostate Cancer
& Prostatic Diseases. 7(4):385, December 2004.
PALIT, V. *; PURI, R.
*; SHAH, T. *; FLANNIGAN, G. M. *; LOADMAN, P. M. +; PHILLIPS,
R. M. +
Intravesical
EOquin (EO9): a new treatment for superficial bladder cancer
- results of phase I study. BJU International - Supplement.
93 Supplement 4:89-90, June 2004.
WILSON, J. R.; PURI, R.
*; PRESCOTT, S.; URWIN, G. H. +
The catheterized
patient undergoing transurethral resection of the prostate:
a survey of the current practice of British urologists. BJU
International. 92(6):589-591, October 2003.
PURI, R.;
SMALING, A.; LLOYD, S. N.
How is follow-up
after transurethral prostatectomy best performed? BJU International.
84(7):795-798, November 1999.
PURI, R.;
SMALING, A.; LLOYD, S. N.
A randomized
study of visual laser ablation of the prostate and TURP: the
ugly truth! British Journal of Urology - Supplement. 79 Supplement
4:61, June 1997.
|
